Pfizer Inc. (NYSE:PFE) Shares Acquired by Chatham Capital Group Inc.

Chatham Capital Group Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.1% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 31,594 shares of the biopharmaceutical company’s stock after buying an additional 1,237 shares during the period. Chatham Capital Group Inc.’s holdings in Pfizer were worth $877,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. VisionPoint Advisory Group LLC boosted its stake in shares of Pfizer by 52,350.0% during the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 1,047 shares during the period. GoalVest Advisory LLC lifted its position in Pfizer by 304.9% in the fourth quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares during the period. Creekmur Asset Management LLC acquired a new stake in Pfizer in the fourth quarter valued at about $32,000. Trivant Custom Portfolio Group LLC lifted its position in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the period. Finally, Tennessee Valley Asset Management Partners acquired a new stake in Pfizer in the fourth quarter valued at about $36,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the stock. Morgan Stanley raised their price objective on shares of Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research report on Thursday, May 2nd. BMO Capital Markets reiterated an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, June 26th. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Nine research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $35.54.

Pfizer Price Performance

Shares of Pfizer stock opened at $27.98 on Monday. The business’s fifty day moving average price is $27.90 and its 200 day moving average price is $27.69. Pfizer Inc. has a twelve month low of $25.20 and a twelve month high of $37.80. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $158.55 billion, a P/E ratio of -466.26, a PEG ratio of 1.10 and a beta of 0.69.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The company had revenue of $14.88 billion for the quarter, compared to the consensus estimate of $13.87 billion. During the same period last year, the business posted $1.23 EPS. The company’s quarterly revenue was down 19.5% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. The ex-dividend date is Thursday, July 25th. This represents a $1.68 annualized dividend and a yield of 6.00%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.